Smoking Cessation
Conditions
Brief summary
Tobacco use is the leading preventable cause of death in the US and a major driver of health disparities. Among our tools for reducing the harms of tobacco is lung cancer screening (LCS). This study will combine a review of existing qualitative and quantitative data on barriers to lung cancer screening and smoking cessation in underserved populations, a quantitative analysis of predictors of lung cancer screening and smoking cessation treatment use among Massachusetts Federally Qualified Health Centers (FQHC)s, and a stakeholder advisory group to synthesize these data and select implementation strategies that reflects the critical determinants and the strengths and resource constraints of the Federally Qualified Health Centers (FQHC) context.
Detailed description
Aim 1) To design an implementation strategy that targets critical components in the delivery of SCT or LCS services for patients who smoke. Aim 2) To assess the acceptability, appropriateness and feasibility of the implementation strategy among community health center staff.
Interventions
OTHERQualitative Group Interviews
One time interview, 60-90 minutes
OTHERStakeholder advisory group
The team will meet with the stakeholder advisory group four times for 1-2 hours each
Sponsors
National Cancer Institute (NCI)
University of Colorado, Denver
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
FQHC implementation team including staff in the intervention FQHCs and their lung screening partners
Exclusion criteria
FQHC staff or partners who leave the organization before end of study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of Intervention Measure | End of study, up to 16 weeks | Feasibility of Intervention Measure, 5-point Likert scales (range 1-5), higher values reflect favorable outcomes |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acceptability of Intervention Measure | End of study, up to 16 weeks | Acceptability of Intervention Measure, 5-point Likert scales (range 1-5), higher values reflect favorable outcomes |
| Intervention Appropriateness Measure | End of study, up to 16 weeks | Intervention appropriateness measure, 5-point Likert scales (range 1-5), higher values reflect favorable outcomes |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Stakeholder Advisory Group To co-design an implementation strategy that targets critical components in the delivery of SCT or LCS services for patients who smoke.
Convene a stakeholder advisory group (CHC providers, quality improvement specialists, community engagement staff, and specialty providers) to review the results of the literature review and quantitative analysis of deidentified data in order to select a set of implementation strategies from a menu of strategies to implement. The team will meet with the stakeholder advisory group five to six times for 0.5-1 hours each.
Qualitative Group Interviews: One time interview, 60-90 minutes
Stakeholder advisory group: The team will meet with the stakeholder advisory group five to six times for 0.5-1 hours each | 8 |
| Total | 8 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Did not participate in survey | 2 |
Baseline characteristics
| Characteristic | Stakeholder Advisory Group | — |
|---|---|---|
| Age, Categorical <=18 years | 0 Participants | — |
| Age, Categorical >=65 years | 0 Participants | — |
| Age, Categorical Between 18 and 65 years | 8 Participants | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Region of Enrollment United States | 8 participants | — |
| Sex: Female, Male Female | 7 Participants | — |
| Sex: Female, Male Male | 1 Participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 8 |
| other Total, other adverse events | 0 / 8 |
| serious Total, serious adverse events | 0 / 8 |
Outcome results
Primary
Feasibility of Intervention Measure
Feasibility of Intervention Measure, 5-point Likert scales (range 1-5), higher values reflect favorable outcomes
Time frame: End of study, up to 16 weeks
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stakeholder Advisory Group | Feasibility of Intervention Measure | 4 units on a scale |
Secondary
Acceptability of Intervention Measure
Acceptability of Intervention Measure, 5-point Likert scales (range 1-5), higher values reflect favorable outcomes
Time frame: End of study, up to 16 weeks
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stakeholder Advisory Group | Acceptability of Intervention Measure | 4 units on a scale |
Secondary
Intervention Appropriateness Measure
Intervention appropriateness measure, 5-point Likert scales (range 1-5), higher values reflect favorable outcomes
Time frame: End of study, up to 16 weeks
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stakeholder Advisory Group | Intervention Appropriateness Measure | 4 units on a scale |